aap Implantate AG, a medical technology company listed on the Frankfurt Stock Exchange in the Prime Standard segment and active in medical biomaterials, fracture healing and joint replacement, achieved in the first six months of the financial year 2008 - according to preliminary figures - a sales growth of 29% to EUR 16.4 million (first half of 2007: EUR 12.7 million).
Sales growth was mainly achieved by the above-average development of the trauma & orthopaedics segment of aap (+80% to EUR 7.0 million) while the aap bio implants group, which specialises in medical biomaterials, showed a sales growth of approx. 7% to EUR 9.4 million. aap expects considerably double-digit growth rates for the biomaterials segment during the second half of the year.
In EUR million 2008 2007 Change
Sales 1st half year 16.4 12.7 +29%
-thereof Trauma & Orthopaedics 7.0 3.9 +80%
- thereof aap bio implants group 9.4 8.8 +7%
For 2008 aap anticipates an organic sales growth of more than 20%, with above-average impact on the company's operating result and net income. The publication of the full aap Implantate AG six month report 2008 is scheduled for August 13, 2008.
Sales growth was mainly achieved by the above-average development of the trauma & orthopaedics segment of aap (+80% to EUR 7.0 million) while the aap bio implants group, which specialises in medical biomaterials, showed a sales growth of approx. 7% to EUR 9.4 million. aap expects considerably double-digit growth rates for the biomaterials segment during the second half of the year.
In EUR million 2008 2007 Change
Sales 1st half year 16.4 12.7 +29%
-thereof Trauma & Orthopaedics 7.0 3.9 +80%
- thereof aap bio implants group 9.4 8.8 +7%
For 2008 aap anticipates an organic sales growth of more than 20%, with above-average impact on the company's operating result and net income. The publication of the full aap Implantate AG six month report 2008 is scheduled for August 13, 2008.
